LONDON, UNITED KINGDOM--(Marketwired - March 3, 2014) - Allerayde SAB Inc. (OTCQB:ASAB) has recently been advised that statements have been made regarding ASAB on the website of the "IPO Society." Neither Allerayde nor its Board nor Officer have any association with the IPO Society and have not been involved in supplying it with any information and have not provided any form of payment for the information disseminated on the IPO Society website.
ASAB is not aware of the objectives of the IPO Society and investors should not rely upon any purportedly factual information about ASAB or its business on the IPO Society website.
A price spike in ASAB shares, seen in September 2013, has been brought to the attention of the Allerayde Board. Allerayde and the Board can confirm that they were not involved in any activity or promotion at this time and have no knowledge as to the cause of this spike.
About Allerayde SAB, Inc.:
Allerayde SAB, Inc. is engaged in the business of developing and manufacturing an innovative anaphylaxis pen product and other consumer health care products for allergy and eczema patients.
The Company's principal product is the AAAPen®. The AAAPen® is a new epinephrine/adrenaline pen for the emergency treatment of anaphylaxis, the severe allergic shock, which may be identified by various rapid onset symptoms following exposure to certain allergens-such as insect venoms, peanuts, seafood, latex, etc.- that have caused symptoms from different level reactions. When the first signs of anaphylaxis being experienced, the AAAPen® shall be used.
Allerayde is also engaged in developing and manufacturing products for the prevention and relief of allergy, asthma and eczema.
Allerayde SAB, Inc. trades on the Over the Counter Market with the ticker symbol ASAB. For more information about the company please visit our website at: www.alleraydesab.com.